STOCK TITAN
  1. Home
  2. News
  3. MRNA

Moderna Inc - MRNA STOCK NEWS

Welcome to our dedicated news page for Moderna (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moderna's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moderna's position in the market.

News
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Rhea-AI Summary
Moderna, Inc. will host a conference call and webcast to report its Q3 2023 financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
conferences earnings
-
News
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Rhea-AI Summary
Moderna announces positive interim results from Phase 1/2 trial of mRNA-1083, a combination vaccine against influenza and COVID-19. Phase 3 trial to begin for adults 50 and above. mRNA-1083 shows strong immunogenicity and safety profile. Plans for regulatory approval in 2025. Estimated fall 2023 COVID-19 market size in the US is 50 to 100 million doses. Respiratory product sales projected to be $8 billion to $15 billion in 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
clinical trial covid-19
-
News
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
Rhea-AI Summary
Moderna, Inc. warns shareholders against TRC Capital's unsolicited mini-tender offer to purchase up to 1,000,000 shares of Moderna's common stock at $99.00 per share, lower than the closing price of $107.56 per share. Moderna advises shareholders not to tender their shares due to the offer's low price and numerous conditions. Mini-tender offers lack the same level of protections as larger tender offers under U.S. securities laws. Investors are urged to obtain a current market quotation for their shares and exercise caution. TRC Capital has a history of making similar offers for stock of other public companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
Rhea-AI Summary
Moderna receives positive recommendation for updated COVID-19 vaccine in Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
covid-19
-
News
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
Rhea-AI Summary
Moderna's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial. Vaccine pipeline advancing rapidly with completion of RSV BLA filing (mRNA-1345) and enrollment in Phase 3 trials of mRNA-1647, mRNA-1283, and mRNA-4157. Plans to launch up to 15 new products in the next five years. Positive clinical data in mRNA-3705 for rare diseases. Expect data on next-gen COVID and flu combination vaccine, mRNA-1083, in Q4. Expect to provide investor update in Q4. COVID-19 vaccine updated for XBB.1.5 sublineage approved by FDA. Expect to launch combination vaccines for flu/COVID-19 and flu/RSV as early as 2025. CMV vaccine Phase 3 study fully enrolled. Developing vaccines for norovirus and oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
clinical trial
-
News
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
Rhea-AI Summary
Moderna receives FDA approval for updated COVID-19 vaccine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
fda approval covid-19
News
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
Rhea-AI Summary
Moderna, Inc. receives an unsolicited 'mini-tender' offer from TRC Capital Investment Corporation to purchase up to 1,000,000 shares at $107.56 per share, which is 4.44% lower than the closing price on September 1, 2023. Moderna advises shareholders not to tender their shares due to the offer being below market value and subject to conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
Moderna, Inc. to participate in fireside chat at Morgan Stanley's Global Healthcare Conference on September 12th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
conferences
-
News
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
Rhea-AI Summary
Moderna's updated COVID-19 vaccine shows significant increase in neutralizing antibodies against BA.2.86 variant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
clinical trial covid-19
News
Moderna to Host Investor Event - R&D Day and Business Updates
Rhea-AI Summary
Moderna to host Investor Event - R&D Day and Business Updates on September 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
conferences
Stock MRNA logo
Moderna Inc

Nasdaq:MRNA

MRNA Rankings

#313 Ranked by Market Cap
#4725 Ranked by Stock Gains
N/A Ranked by Dividends

MRNA Stock Data

40.26B
344.86M
9.63%
73.16%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About MRNA

moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a